Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390149 | 0.90 | RAB9A (0.40) | KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL2773399 | 0.90 | RAB9A (0.40) | KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL4550273 | 0.84 | CYP4F2 (0.41) | KMT2AMEN1KDM4EMAPT | |
| SCHEMBL6134733 | 0.83 | ALDH1A1 (0.38) | KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL19049584 | 0.82 | KMT2A (0.39) | KMT2AMEN1RAB9ANPC1KDM4E | |
| SCHEMBL796623 | 0.82 | ALDH1A1 (0.36) | — | |
| SCHEMBL12396094 | 0.81 | EPHX2 (0.46) | KMT2AMEN1NPC1 | |
| SCHEMBL19601422 | 0.81 | SMN1; SMN2 (0.49) | KMT2AMEN1 | |
| SCHEMBL12522184 | 0.81 | KMT2A (0.43) | KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL8222331 | 0.80 | GAA (0.37) | CYP2C9CYP2C19MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| CN-100447140-C | 7- ([1,4] di * alk-2-yl) -benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | CN | disclosed |
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1615919-B1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| CN-1871244-A | Thiazolopyridine derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-11-29 | — | — | CN | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| CN-1774437-A | 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1615919-A1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-6872833-B2 | Adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2004089949-A1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KMT2A 3938/4885MEN1 4842/4885RAB9A 4766/4885 |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | ADORA1, ADORA2A, ADORA3 | KMT2A 2846/4885MEN1 2802/4885RAB9A 1366/4885 |
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | KMT2A 2943/4885MEN1 3673/4885RAB9A 2296/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KMT2A 3938/4885MEN1 4842/4885RAB9A 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.